June 17, 2021 09:59 AM EDT

In a move to boost its natural killer candidates, Senti Bio will build out its own San Francisco manufacturing facility

Josh Sullivan

Silicon Valley synthetic biology player and Roche collaborator Senti Bio has been hush-hush about much of its science since it was founded in 2016, but …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In a move to boost its natural killer candidates, Senti Bio will build out its own San Francisco manufacturing facility

Josh Sullivan

Sign up to read this article for free.

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Outlook's shares crash as wet AMD drug flunks Phase 3 test

Novartis to cut 139 jobs in NJ as part of commercial refocus

In a move to boost its nat­ur­al killer can­di­dates, Sen­ti Bio will build out its own San Fran­cis­co man­u­fac­tur­ing fa­cil­i­ty

Josh Sullivan

Sign up to read this article for free.

more like this

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Out­look's shares crash as wet AMD drug flunks Phase 3 test

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

In a move to boost its natural killer candidates, Senti Bio will build out its own San Francisco manufacturing facility

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Outlook's shares crash as wet AMD drug flunks Phase 3 test

Novartis to cut 139 jobs in NJ as part of commercial refocus